Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Document type

Article

Version

Published version

Publication date

Publication license

cc by (c) Hueso Val, Miguel et al, 2021
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/181697

NcRNAs in Therapeutics: Challenges and Limitations in Nucleic Acid-Based Drug Delivery

Journal Title

Director/Tutor

Journal ISSN

Volume Title

Abstract

Non-coding RNAs (ncRNAs) are emerging therapeutic tools but there are barriers to their translation to clinical practice. Key issues concern the specificity of the targets, the delivery of the molecules, and their stability, while avoiding "on-target" and "off-target" side effects. In this "ncRNA in therapeutics" issue, we collect several studies of the differential expression of ncRNAs in cardiovascular diseases, bone metabolism-related disorders, neurology, and oncology, and their potential to be used as biomarkers or therapeutic targets. Moreover, we review recent advances in the use of antisense ncRNAs in targeted therapies with a particular emphasis on their basic biological mechanisms, their translational potential, and future trends.

Subject (English)

Citation

Citation

HUESO VAL, Miguel, et al. NcRNAs in Therapeutics: Challenges and Limitations in Nucleic Acid-Based Drug Delivery. International Journal of Molecular Sciences. 2021. Vol. 22, num. 21, pags. 11596. ISSN 1422-0067. [consulted: 13 of August of 2026]. Available at: https://hdl.handle.net/2445/181697

Export metadata

JSON - METS

Share record